renizgamlogene autogedemcel

Renizgamlogene autogedemcel (reni-cel) is an investigational gene-edited autologous hematopoietic stem cell therapy designed to treat sickle cell disease (SCD). Its mechanism involves inducing sustained production of fetal hemoglobin (HbF) by reactivating $\gamma$-globin gene (HBG1/2) expression. This is achieved through gene editing of cluster of differentiation 34+ (CD34+) cells at the BCL11A transcriptional repressor binding site in the HBG1/2 promoters, utilizing an *Acidaminococcus* sp. CRISPR-associated protein 12a (AsCas12a) nuclease. This genomic modification mimics natural mutations associated with hereditary persistence of HbF, which are known to alleviate symptoms of $\beta$-hemoglobinopathies. Preclinical studies demonstrated high editing efficiency, robust HbF production, and a significant reduction in sickling of erythroid progeny from SCD patients. The drug is currently being evaluated in the Phase I/II RUBY trial for patients with severe SCD.